BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer.

about

BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer.

Item

http://www.wikidata.org/entity/Q49771879

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

BRAF V600E mutation is a predi ...... or stage IV colorectal cancer.

@en

BRAF V600E mutation is a predi ...... or stage IV colorectal cancer.

@nl

type

Item

label

BRAF V600E mutation is a predi ...... or stage IV colorectal cancer.

@en

BRAF V600E mutation is a predi ...... or stage IV colorectal cancer.

@nl

prefLabel

BRAF V600E mutation is a predi ...... or stage IV colorectal cancer.

@en

BRAF V600E mutation is a predi ...... or stage IV colorectal cancer.

@nl

P1476

BRAF V600E mutation is a predi ...... for stage IV colorectal cancer

@en

P2093

Ajay Goel

http://www.w3.org/2001/XMLSchema#string

Hideyuki Mishima

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Kishimoto

http://www.w3.org/2001/XMLSchema#string

Ryo Inada

http://www.w3.org/2001/XMLSchema#string

Takashi Kawai

http://www.w3.org/2001/XMLSchema#string

Tatsuya Morikawa

http://www.w3.org/2001/XMLSchema#string

Toshiyoshi Fujiwara

http://www.w3.org/2001/XMLSchema#string

Yoshiko Mori

http://www.w3.org/2001/XMLSchema#string

Yuzo Umeda

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable Stage IV colorectal cancer

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability

Comprehensive molecular characterization of human colon and rectal cancer

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Targeting RAS signalling pathways in cancer therapy

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics

A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer

P304

2195-2201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2017.7553

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Takeshi Nagasaka

P577

2017-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29434925

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5776948

http://www.w3.org/2001/XMLSchema#string